Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 119 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Psilocybin, Psychotherapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
26 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Not yet recruiting Phase 1Phase 2 Interventional

Psilocybin for Treatment of OCD-2

NCT06992999
Conditions
Obsessive - Compulsive Disorder
Interventions
Low Dose Psilocybin, High Dose Psilocybin
Drug
Lead sponsor
Francisco A Moreno
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Psilocybin Administration With 5-HT1a Blockade

NCT07565493
Conditions
Psychedelic Effects in Healthy Volunteers
Interventions
Pindolol, Placebo, Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin

NCT07721467
Conditions
Alzheimer's Disease
Interventions
Psilocybin, Cognitive Training
Drug · Other
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
65 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Major Depression
Interventions
Psilocybin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Portland, Oregon + 2 more
Conditions
Obsessive-Compulsive Disorder
Interventions
Psilocybin 10 mg, Psilocybin 20 mg, Psilocybin 30 mg
Drug
Lead sponsor
Francisco A Moreno
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Parkinson Disease, Depression
Interventions
Psilocybin, Pimavanserin
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Anhedonia, Emotional Blunting
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Conditions
Treatment Resistant Depression, Substance Use Disorders
Interventions
Psilocybin
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Indianapolis, Indiana
Recruiting Phase 2 Interventional Accepts healthy volunteers

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

NCT05452772
Conditions
Tobacco Use Disorder
Interventions
Psilocybin, Niacin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • New York, New York
Conditions
Distress, Depression, Grief
Interventions
Psilocybin, Modified brief Supportive Expressive Group Therapy
Drug · Behavioral
Lead sponsor
Joshua Woolley
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Active, not recruiting Phase 3 Interventional

Psilocybin for Major Depressive Disorder (MDD)

NCT06308653
Conditions
Depressive Disorder, Major
Interventions
Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
Drug · Behavioral
Lead sponsor
Usona Institute
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more
Conditions
Alcohol Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Not listed Phase 1 Interventional Accepts healthy volunteers

Northwest Therapies Trauma Psilocybin Study Compassionate Use Study

NCT05042466
Conditions
Trauma, Nervous System
Interventions
Trauma
Drug
Lead sponsor
NWTraumatherapies
Network
Eligibility
21 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bozeman, Montana
Conditions
Treatment-Resistant Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charlestown, Massachusetts
Conditions
Opioid-Related Disorders, Pain Management, Pain Management and Care, Advanced Cancer, Advanced Cancers
Interventions
Psilocybin
Drug
Lead sponsor
Yvan Beaussant, MD, MSci
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Phase 1 Interventional Accepts healthy volunteers

Open-Label Psilocybin Study in Transdiagnostic Population

NCT06442423
Conditions
Transdiagnostic, Depression - Major Depressive Disorder, Anxiety, PTSD Symptoms, PTSD, Substance Use, Substance Use Disorder (SUD), OCD
Interventions
Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Post Traumatic Stress Disorder, Depression - Major Depressive Disorder
Interventions
Psilocybin + MBCT therapy, Active Comparator: Psilocybin with Support Only
Combination Product
Lead sponsor
Anthony P King
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Major Depressive Disorder
Interventions
Psilocybin, Pimavanserin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Terminated No phase listed Observational Accepts healthy volunteers

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

NCT06624137
Conditions
OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer, Migraine, PTSD, PTSD - Post Traumatic Stress Disorder, Addiction, Tobacco Use Disorder, Obsessive Compulsive Disorder (OCD), Opioid Use Disorder
Interventions
Serotonergic Psychedelic, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Hamden, Connecticut • West Haven, Connecticut
Conditions
Irritable Bowel Syndrome
Interventions
TRYP-0082, Psychotherapy
Drug · Behavioral
Lead sponsor
TRYP Therapeutics
Industry
Eligibility
21 Years to 64 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Depression, Anxiety, Psilocybin-Assisted Psychotherapy, Advanced Cancer
Interventions
Psilocybin, Niacin
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 2 Interventional Results available

Effects of Psilocybin in Major Depressive Disorder

NCT03181529
Conditions
Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
40
States / cities
Tuscon, Arizona • Culver City, California • Garden Grove, California + 30 more